China surges past India in drug discovery work

China's willingness to get aggressive in protecting biopharma's intellectual property is being credited with its surge past India in the total number of completed and ongoing clinical trials. An Indian court's ruling against Novartis on Gleevec is helping accelerate a trend away from the subcontinent. There's no sign that India's generic drug industry is flagging, though, with homegrown companies aggressively going after new markets--including biosimilars. We may be seeing a trend here that will take China forward as a new base for drug discovery work based on high quality and low costs while India sees generics grow ever stronger.

- here's the research from Seeking Alpha

ALSO: China's generics industry is gearing up for an onslaught on the U.S. market. Report

Related Articles:
China now leads India in ongoing clinical trials. Report
China's pharma market steams ahead. Report
China pushes drug development as R&D soars. Report
China to overhaul drug safety regulations. Report
Bridge Pharma sees growth in China drug studies. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.